Traws Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Traws Pharma
TRAW Stock   2.96  0.17  6.09%   
Traws Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Traws Pharma's valuation are provided below:
Gross Profit
2.8 M
Market Capitalization
19.4 M
Enterprise Value Revenue
5.5778
Revenue
2.8 M
Earnings Share
(1.82)
There are over one hundred nineteen available fundamental trend indicators for Traws Pharma, which can be analyzed over time and compared to other ratios. All traders should should double-check Traws Pharma's current fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable. Market Cap is likely to drop to about 15.1 M in 2026. Enterprise Value is likely to climb to about (8.2 M) in 2026

Traws Pharma Total Revenue

193,230

Check Traws Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Traws Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.3 K, Interest Expense of 1.7 K or Selling General Administrative of 8.7 M, as well as many indicators such as Price To Sales Ratio of 60.27, Dividend Yield of 0.0 or Days Sales Outstanding of 2.7 K. Traws financial statements analysis is a perfect complement when working with Traws Pharma Valuation or Volatility modules.
  
Build AI portfolio with Traws Stock
Check out the analysis of Traws Pharma Correlation against competitors.
For more information on how to buy Traws Stock please use our How to Invest in Traws Pharma guide.

Traws Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets28.4 M22.5 M32.5 M
Pretty Stable
Other Current Liabilities4.1 M2.8 M4.9 M
Slightly volatile
Total Current Liabilities8.4 M10.4 M10.5 M
Slightly volatile
Property Plant And Equipment Net8.6 K9 K188.8 K
Slightly volatile
Current Deferred Revenue193.2 K203.4 K553.2 K
Slightly volatile
Accounts Payable5.3 M9.4 M5.2 M
Slightly volatile
Cash24.4 M19.2 M27.9 M
Very volatile
Non Current Assets Total9.4 K9.9 K251.1 K
Slightly volatile
Non Currrent Assets Other85590062.3 K
Slightly volatile
Cash And Short Term Investments26.7 M19.2 M30.4 M
Pretty Stable
Net Receivables2.1 M2 M536.3 K
Slightly volatile
Common Stock Shares Outstanding1.9 M1.8 M475.3 K
Slightly volatile
Liabilities And Stockholders Equity28.4 M22.5 M32.5 M
Pretty Stable
Non Current Liabilities Total26.3 M40.6 M38.7 M
Slightly volatile
Other Current Assets1.2 M1.7 M1.4 M
Pretty Stable
Total Liabilities34.7 M50.9 M49.1 M
Slightly volatile
Total Current Assets28.2 M22.5 M32.2 M
Pretty Stable
Common Stock39.3 K41.4 K155.3 K
Very volatile
Other Stockholder Equity422.1 M710.2 M361.2 M
Slightly volatile
Short Term Investments32 M36 M39.3 M
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile
Inventory1.7 M1.6 M762.8 K
Slightly volatile
Property Plant And Equipment Gross83.2 K96.6 K74 K
Slightly volatile
Capital Stock30.8 K32.4 K123 K
Pretty Stable
Net Working Capital18.8 M12.1 M14.5 M
Slightly volatile

Traws Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization10.3 K10.8 K136.7 K
Slightly volatile
Interest Expense1.7 K1.8 K510.3 K
Slightly volatile
Selling General Administrative8.7 M11.1 M10 M
Pretty Stable
Total Revenue193.2 K203.4 K4.6 M
Slightly volatile
Gross Profit183 K192.6 K4.5 M
Slightly volatile
Other Operating Expenses28.6 M44.6 M35.5 M
Slightly volatile
Research Development157.4 M149.9 M45.8 M
Slightly volatile
Total Operating Expenses28.5 M44.6 M35.3 M
Slightly volatile
Cost Of Revenue10.3 K10.8 K67.4 K
Slightly volatile
Reconciled Depreciation15.2 K13.8 K13.4 K
Slightly volatile

Traws Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.2 M1.3 M2.3 M
Slightly volatile
Begin Period Cash Flow23.6 M18.7 M27.3 M
Very volatile
Depreciation10.3 K10.8 K136.9 K
Slightly volatile
End Period Cash Flow24.4 M19.2 M27.9 M
Very volatile
Other Cashflows From Investing Activities12 K13.5 K14.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio60.2754.9178.7816
Very volatile
Days Sales Outstanding2.7 K2.6 K518
Slightly volatile
Stock Based Compensation To Revenue3.65.183.2978
Slightly volatile
Capex To Depreciation1.090.791.7973
Pretty Stable
Payables Turnover0.00160.00170.0114
Slightly volatile
Sales General And Administrative To Revenue28.4748.9419.1397
Slightly volatile
Research And Ddevelopement To Revenue545519118
Slightly volatile
Capex To Revenue0.120.07120.082
Slightly volatile
Cash Per Share15.0115.865.3 K
Slightly volatile
Days Payables Outstanding235.3 K224.1 K203.9 K
Slightly volatile
Net Debt To EBITDA0.140.151.0147
Very volatile
Current Ratio3.892.493.3094
Very volatile
Receivables Turnover0.140.1518.6297
Pretty Stable
Capex Per Share0.01820.0192432
Slightly volatile
Revenue Per Share0.160.1716.6 K
Slightly volatile
Interest Debt Per Share5.685.972.3 K
Slightly volatile
Operating Cycle2.7 K2.6 K518
Slightly volatile
Days Of Payables Outstanding235.3 K224.1 K203.9 K
Slightly volatile
Ebt Per Ebit3.193.041.3752
Slightly volatile
Quick Ratio3.892.493.3062
Very volatile
Net Income Per E B T0.360.380.7963
Slightly volatile
Cash Ratio2.461.672.7967
Pretty Stable
Days Of Sales Outstanding2.7 K2.6 K518
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.780.90.9751
Slightly volatile
Fixed Asset Turnover34.5725.9929.6145
Very volatile
Price Sales Ratio60.2754.9178.7816
Very volatile
Asset Turnover0.00990.01040.1404
Slightly volatile
Gross Profit Margin1.071.090.9707
Slightly volatile

Traws Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.1 M15.9 M75.2 M
Slightly volatile

Traws Fundamental Market Drivers

About Traws Pharma Financial Statements

Traws Pharma investors use historical fundamental indicators, such as Traws Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Traws Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue203.4 K193.2 K
Total Revenue203.4 K193.2 K
Cost Of Revenue10.8 K10.3 K
Stock Based Compensation To Revenue 5.18  3.60 
Sales General And Administrative To Revenue 48.94  28.47 
Research And Ddevelopement To Revenue 518.94  544.88 
Capex To Revenue 0.07  0.12 
Revenue Per Share 0.17  0.16 
Ebit Per Revenue(251.11)(238.55)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HITIHigh Tide
HITIHigh Tide
BACBank of America

Additional Tools for Traws Stock Analysis

When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY